Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.
This study examines the response to dexamethasone-doxorubicin-vincristine (DAV) therapy, followed by conditioning regimen and autologous stem cells transplantation (ASCT) in patients with multiple myeloma in relation with the presence of polymorphisms in genes involved in drug metabolism (GSTP1) and DNA synthesis (TYMS). GSTP1 G313G genotype (OR=5.49; 95% CI, 1.3-22.5, p=0.02) and TYMS A227A genotype (OR=3.41; 95% CI, 1.3-8.9, p=0.01) resulted significantly associated with a poor response following chemotherapy and the risk increased for the combined genotype (OR=13.54; 95% CI, 2.0-91.3, p=0.01). TYMS T157T genotype was significantly associated with a poor response after ASCT (OR=4.60; 95% CI, 1.2-16.9, p=0.02). Pre-therapeutic individual determination of the GSTP1 and TYMS polymorphisms could help in choosing the most appropriate protocol.
Maggini
Valentina
V
Department of Biology, Pisa University, Pisa, Italy.
Buda
Gabriele
G
Galimberti
Sara
S
Conidi
Elena
E
Giuliani
Nicola
N
Morabito
Fortunato
F
Genestreti
Giovenzio
G
Iacopino
Pasquale
P
Rizzoli
Vittorio
V
Barale
Roberto
R
Petrini
Mario
M
Rossi
Anna Maria
AM
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D005260:Female; D051549:Glutathione S-Transferase pi / Q000235:genetics*; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000235:genetics* / Q000628:therapy*; D015376:Nimustine / Q000627:therapeutic use; D020641:Polymorphism, Single Nucleotide; D033581:Stem Cell Transplantation; D016019:Survival Analysis; D013940:Thymidylate Synthase / Q000235:genetics*; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
D015376:Nimustine; D014750:Vincristine; D003606:Dacarbazine; D003520:Cyclophosphamide; D013940:Thymidylate Synthase; D051549:Glutathione S-Transferase pi; D008558:Melphalan